Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Cash & Current Investments came in at $22.1 billion in Q1 2026, down 43.14% year-on-year from $38.8 billion in Q1 2025, and up 9.7% quarter-over-quarter from $20.1 billion in Q4 2025.
Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Cash & Current Investments across 18 years of filings, most recently posting $22.1 billion for Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $22.1 billion, down 43.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.1 billion (down 43.14% YoY), and the FY2025 annual result was $20.1 billion, down 18.02% from the prior year.
- Cash & Current Investments came in at $22.1 billion for Q1 2026 at Johnson & Johnson, up from $20.1 billion in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $38.8 billion in Q1 2025 to a low of $18.6 billion in Q3 2025.
- The 5-year median for Cash & Current Investments is $24.6 billion (2023), against an average of $25.9 billion.
- Across the five-year window, Cash & Current Investments jumped 47.92% in 2025 and tumbled 43.14% in 2026, its largest moves.
- Johnson & Johnson's Cash & Current Investments stood at $34.1 billion in 2022, then sank by 32.72% to $22.9 billion in 2023, then gained by 6.96% to $24.5 billion in 2024, then fell by 18.02% to $20.1 billion in 2025, then advanced by 9.7% to $22.1 billion in 2026.
- The last three Cash & Current Investments figures came in at $22.1 billion (Q1 2026), $20.1 billion (Q4 2025), and $18.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 4.38 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 22.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 10.49 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 100.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 22.05 Bn |
| Dec 28, 2025 | 20.10 Bn |
| Sep 28, 2025 | 18.56 Bn |
| Jun 29, 2025 | 18.88 Bn |
| Mar 30, 2025 | 38.78 Bn |
| Dec 29, 2024 | 24.52 Bn |
| Sep 29, 2024 | 20.30 Bn |
| Jun 30, 2024 | 25.48 Bn |
| Mar 31, 2024 | 26.22 Bn |
| Dec 31, 2023 | 22.93 Bn |
| Oct 1, 2023 | 23.51 Bn |
| Jul 2, 2023 | 28.51 Bn |
| Apr 2, 2023 | 24.61 Bn |
| Jan 1, 2023 | 22.28 Bn |
| Oct 2, 2022 | 34.08 Bn |
| Jul 3, 2022 | 32.57 Bn |
| Apr 3, 2022 | 30.39 Bn |
| Jan 2, 2022 | 31.61 Bn |
| Oct 3, 2021 | 31.00 Bn |
| Jul 4, 2021 | 25.31 Bn |